Market Access BIO-Europe Spring, Portugal: Propelling new wave innovation BIO-Europe Spring arrived in Lisbon, Portugal yesterday, running from 23rd to 25th March.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
